Hyperion DeFi (NASDAQ:HYPD) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Hyperion DeFi (NASDAQ:HYPD) from a strong sell rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Chardan Capital cut their target price on Hyperion DeFi from $8.25 to $7.30 and set a “buy” rating for the company in a research note on Monday, June 8th. Finally, Cantor Fitzgerald raised their target price on Hyperion DeFi from $4.00 to $6.60 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Hyperion DeFi currently has an average rating of “Hold” and a consensus target price of $6.95.

Hyperion DeFi Trading Up 2.0%

Shares of HYPD stock opened at $3.02 on Tuesday. The stock has a market capitalization of $45.78 million, a price-to-earnings ratio of -0.30 and a beta of 2.49. The company’s fifty day simple moving average is $3.30 and its two-hundred day simple moving average is $3.47. Hyperion DeFi has a 1 year low of $2.49 and a 1 year high of $16.12. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.97 and a quick ratio of 1.97.

Insider Buying and Selling at Hyperion DeFi

In other news, insider Hyunsu Jung purchased 7,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average price of $3.70 per share, with a total value of $25,900.00. Following the completion of the acquisition, the insider owned 1,384,676 shares in the company, valued at $5,123,301.20. This trade represents a 0.51% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Hyperion DeFi

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC purchased a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $38,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Hyperion DeFi during the fourth quarter worth about $40,000. Price T Rowe Associates Inc. MD bought a new position in shares of Hyperion DeFi in the fourth quarter worth approximately $73,000. Formidable Asset Management LLC bought a new position in shares of Hyperion DeFi in the fourth quarter worth approximately $83,000. Finally, State Street Corp bought a new stake in Hyperion DeFi during the fourth quarter valued at approximately $92,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.